|
BACKGROUND: Arsenic trioxide delivers high rates of complete clinical
remission in patients with relapsed/refractory acute promyelocytic leukaemia
(APL), and is associated with high rates of molecular remission as indicated by
PCR negativity for the PML-RARalpha gene. OBJECTIVE: Mitochondria are considered
to be the primary intracellular target of arsenic trioxide, and preclinical and
mechanistic studies suggest that this agent may have broad applicability in
haematological and other malignancies. Investigations of this agent are ongoing
in a range of haematological malignancies, and studies in newly diagnosed APL,
acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), multiple myeloma
(MM) and chronic myelogenous leukaemia (CML) are reviewed here using published
articles and presentations at international congresses to June 2004.
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML Yahoo! Groups Links
|
